The total number of records retrieved from this search are 8. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2980	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman neck and squamous carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell line7.68E+3 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration2.4 × 10⁸ pfu	In-vitro result97.2 +/- 4.7% cell viable after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID25890191
IDOV_4663	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.001 MOI	In-vitro result82% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4664	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.005 MOI	In-vitro result60% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4665	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.01 MOI	In-vitro result55% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4666	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.05 MOI	In-vitro result40% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4667	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.1 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4668	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration0.5 MOI	In-vitro result38% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105
IDOV_4669	Virus nameHerpes simplex virus	Virus strainRAMBO	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAntiangiogenic Vstat120 expressing virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman squamous cell carcinoma cell line	Cell lineUM-SCC-47	Concentration of cell lineNA	In-vitro toxicityNA	AssayStatistical analysis	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after 2 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduce antitumor immune response	Clinical trialNA	PMID27119105